UCB Set to Present New Findings on RYSTIGGO® and ZILBRYSQ® for gMG at 2025 AANEM Meeting

UCB to Present New Insights on gMG Treatments at AANEM 2025

UCB, a leader in biopharmaceuticals, announced an upcoming presentation of innovative data at the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session. Scheduled to take place from October 29 to November 1, 2025, in San Francisco, the company will unveil findings related to its two significant treatments: RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ® (zilucoplan) targeted towards generalized myasthenia gravis (gMG).

This revelation underscores UCB’s commitment to advancing treatment options for individuals suffering from gMG, marked by a unique array of 18 abstracts including an oral presentation. Highlights of the data encompass significant insights from recent post hoc analyses focusing on corticosteroid dose tapering strategies when treating with RYSTIGGO® and the overall impact of ZILBRYSQ® on quality of life indicators within the context of this complex autoimmune condition.

UCB's Dedication to gMG Management

Kimberly Moran, PhD, Senior Vice President and Head of UCB’s U.S. Rare Diseases division, emphasized the importance of these findings, saying that “people living with gMG manage unpredictable symptoms daily, which can severely reduce their ability to carry out everyday activities.” UCB is not only committed to pioneering innovative treatments but also supports ongoing collaboration within the healthcare community to address these patients' unique concerns.

At the core of UCB's mission is the belief that empowering patients through innovative healthcare solutions is essential. Donatello Crocetta, Global Head of Medical Affairs and Chief Medical Officer at UCB, commented, “Our presentations at the AANEM Annual Meeting and MGFA Scientific Session reflect our focus on developing treatment options that combine clinical efficacy with enhancements in the quality of life for individuals coping with gMG.”

Key Data Highlights to be Presented

1. Corticosteroid Tapering Analysis:
A spotlight will be given to data from the double-blind Phase 3 MycarinG study and its open-label extensions, specifically looking into how corticosteroid doses can be tapered safely during treatment with RYSTIGGO®.

2. Long-term Safety of Rozanolixizumab:
The long-term safety profiles of cyclic rozanolixizumab treatment in gMG will be discussed, providing insights into its potential for sustained therapeutic application.

3. QoL Improvement with Zilucoplan:
Preliminary data will reveal the impact of zilucoplan on the Myasthenia Gravis Quality of Life – 15 item revised (MG-QoL15r) total scores, showcasing its benefits on patients' daily well-being.

4. Real-World User Insights:
Analyzing data from the HumaMG app, UCB will share crucial real-world insights regarding user characteristics and adherence patterns among those managing myasthenia gravis.

Upcoming Panel Discussion

UCB has also lined up a panel discussion titled "Continuing the Conversation: Subpopulations with Barriers to Care in Myasthenia Gravis," addressing the various challenges faced by patients and caregivers alike. A UCB-sponsored therapeutic update on expert perspectives regarding gMG treatments will also be part of the agenda at the meeting.

As outlined by UCB, gMG remains a rare but impactful autoimmune disease characterized by muscle weakness and fatigue, necessitating targeted therapeutic approaches like those offered through their innovative treatments. By opening pathways to enhanced patient support and treatment strategies, UCB continues to reinforce its dedication to improving the lives of those affected by this challenging condition.

For more information on UCB and its innovative medicines, please visit UCB's official website.

About UCB

UCB, based in Brussels, is recognized globally for its focused efforts in creating innovative medicines aimed at improving the lives of individuals grappling with severe diseases of the immune and central nervous system, with a workforce of approximately 9,000 people across 40 countries. UCB achieved a notable revenue of €6.15 billion in 2024, reflecting its dedicated service and impact in the biopharmaceutical sector.